

Zika virus (strain Zika SPH2015) Envelope Protein (ZIKV-E) ELISA Kit | ZIKV-E elisa kit

Zika virus (strain Zika SPH2015) Envelope Protein (ZIKV-E) ELISA Kit

CATALOG #
AAA258461

REACTIVITY
Zika Virus (ZIKV)


PRODUCT SYNONYMS

Zika virus (strain Zika SPH2015) Envelope Protein (ZIKV-E); Zika virus (strain Zika SPH2015) Envelope Protein (ZIKV-E) ELISA Kit; ZIKV-E elisa kit

PRODUCT SPECIFICATIONS

Reactivity	Zika Virus (ZIKV)
Specificity	The kit has been verified by high purity, recombinant Zika virus (strain Zika SPH2015) Envelope Protein.
Assay Type	Solid Phase Sandwich ELISA (quantitative)
Sample Types	Recombinant protein
Detection Range	187.5-12000pg/mL
Sensitivity	99.72pg/mL
Conjugation	HRP
Materials Provided	1. 96 well microplate coated with Capture Antibody 2. Detection Antibody conjugated to HRP 3. Standards 4. Wash Buffer Concentrate 5. Dilution Buffer Concentrate 6. Color Reagent A 7. Color Reagent B 8. Stop Solution

IMAGES



Standard Curve (Sample)

This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.

ADDITIONAL INFORMATION

Related Product Information for ZIKV-E elisa kit	This Zika virus (strain Zika SPH2015) Envelope Protein (ZIKV-E) ELISA Kit is an enzyme-linked immunosorbent assay for the quantitative measurement of ZIKV ZIKV Envelope protein in Recombinant protein. It contains recombinant ZIKV ZIKV Envelope, and antibodies raised against the recombinant protein. This ELISA kit is complete and ready-to-use. Background: Envelope of Zika virus is responsible for receptor binding and membrane. Analysis of the envelope protein of Zika, from Brazilian Zika SPH215 (KU321639), indicates predicted B and T cell epitopes in peptides that are consistent with those reported for dengue, YFYF and Japanese encephalitis. The envelope Domain II B cell epitope, to which much dengue non-neutralizing cross-reaction is attributed, is also conserved also in Zika virus, consistent with prior field observations of cross-reactivity with dengue and YF. Domain III of the Zika envelope protein, likely the main specific neutralizing domain, is distinct from recent Brazilian dengue isolates and a recent Peruvian YF isolate (GQ379163), 76% of possible major histocompatibility complex class (MHC) I and MHC II binding peptides and potential B cell linear epitopes are unique to Zika virus.
References	Marina Basarab specialty registrar. et al.Zika virus. BMJ 2016; 352:i1049 doi: 10.1136/bmj.i1049 Pinto Júnior VL, et al. Zika virus: a review to clinicians, Acta Med Port 2015 Nov-Dec;28(6):760-765 L Zammarchi, et al.Zika virus infection in a traveler returning to Europe from Brazil, March 2015 Arturo Galindo-Fraga, et al. Zika virus: A new epidemic on our doorstep. Rev Inves Clin.2015, 67: 329-32

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/zika-elisa-kits/zika-virus-strain-zika-sph2015-envelope-protein-zikv-e/258461>